Original Research Article
Year: 2022 | Month: March | Volume: 9 | Issue: 3 | Pages: 228-236
DOI: https://doi.org/10.52403/ijrr.20220327
A Comparison of Efficacy of Nepafenac 0.1% with Nepafenac 0.3% Drops for the Management of Post-Operative Inflammation and CME in Uneventful Phacoemulsification
Ashok Kumar Nanda1, Sanghamitra Kanungo2, Asish Swain3
1Consultant, Kar Vision Eye Hospital, Bhubaneswar-751007. Odisha
2Consultant Vitreo-Retina & Microsurgery, Kar Vision Eye Hospital, Bhubaneswar-751007. Odisha
3Optometrist, Kar Vision Eye Hospital, Bhubaneswar-751007. Odisha
Corresponding Author: Ashok Kumar Nanda
ABSTRACT
Aim: To compare the efficacy of two topical nonsteroidal anti-inflammatory drops (NSAIDs) used in isolation in controlling inflammation and preventing cystoid macular edema (CME) after uneventful phacoemulsification.
Design: Single armed randomized prospective study
Methods: 200 patients who underwent uneventful phacoemulsification from December 2020 to March 2021 by a single surgeon were randomly assigned to be given one of the two NSAID drops. Among the 200 individuals those were included in the study, 192 patients completed follow up visits at 1 and 6 weeks and were included for analysis of the results. The efficacy of the drugs was evaluated by comparing the grade of pain score, conjunctival hyperemia, anterior chamber (AC) cells, along with best corrected visual acuity (BCVA), central macular thickness (CMT) and intraocular pressure (IOP) recorded at 1 and 6 weeks after surgery.
Results: Between the two NSAID groups, there was no significant difference in pain ratings, AC cell grade, or visual acuity. There was no significant difference in the number of patients experiencing CME at 6 weeks. At 1 and 6 weeks, however, the mean rise in central macular thickness and conjunctival hyperemia in nepafenac 0.3 percent was much smaller.
Conclusion: The efficacy of both the topical NSAIDs was found to be comparable in terms of pain score, AC cells grade and visual acuity. Though occurrence of CME after surgery was similar in both the NSAID’s, subclinical CME was less in Nepafenac 0.3% group both at 1st and 6th week follow up.
Keywords: non-steroidal anti-inflammatory drugs, visual acuity, central macular thickness, cystoid macular edema, phacoemulsification.
[PDF Full Text]